<DOC>
	<DOCNO>NCT01651494</DOCNO>
	<brief_summary>This study double-blind , randomize , placebo-controlled study single dose ( 20mg ) Influenza Antiviral DAS181-F04 3 day . The group nine subject randomly assign DAS181 placebo 2:1 ratio . Subjects admit inpatient clinic minimum night prior first dose . The subject stay inpatient clinic duration dose one day dosing , require come back follow-up visit study day 4 , 6 , 9 , 16 ( +/-1 day ) , 32 ( +/-3 day ) , 90 ( +/-10 day ) . The safety parameter include abnormal laboratory value , adverse event clinical observation .</brief_summary>
	<brief_title>Influenza Antiviral DAS-181-F04 Healthy Adults</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled study . The subject receive single-dose treatment DAS181-F04 placebo target deliver dose 20mg day three day . The subject evaluate day initial dose ( Day -1 ) randomly assign DAS181-F04 placebo 2:1 ratio . Subjects evaluate prior dosing Days 0 , 1 2 . Additional follow-up evaluation occur one day completion dosing ( Day 3 ) Days 4 , 6 , 9 , 16 ( +/-1 day ) , 32 ( +/-3 day ) 90 ( +/-10 day ) . The primary objective determine safety tolerability DAS181-F04 encapsulate dry powder compare placebo administer oral inhalation use dry powder inhaler ( DPI ) healthy adult . The secondary objective investigate pharmacokinetic immunologic profile DAS181 encapsulate dry powder dose dose compare placebo administer oral inhalation use DPI healthy adult . A total 9 subject , healthy male female subject , age 18 45 year enrol . Subjects randomize 2:1 ratio , wherein 6 subject receive active drug 3 subject receive placebo . Subjects may replace subject withdraws within 7 day ( Day 9 ) receipt final study drug dose .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female subject good health opinion site Principal Investigator ( PI ) subinvestigator determine vital sign , medical history , physical exam . Subjects must able verbalize understanding consent form , provide write informed consent verbalize willingness complete study procedure . Be 18 45 year age ( inclusive ) , time screen . Subjects must Body Mass Index ( BMI ) 17.535 . Actual low weight limit may 50 kg , BMI range indicate . No history smoke past six month , regardless clinical relevance . Electrocardiogram ( ECG ) clinically significant abnormality record screen visit : PR interval within 120 200ms , QRS interval &lt; 120ms , confirm QTc interval &lt; /= 440ms . Blood pressure within normal limit ( systolic 86 140mmHg ; diastolic 50 90 mmHg ) heart rate 45 100 beat per minute . Chest Xray show clinically significant abnormality . Forced expiratory volume 1 second ( FEV1 ) great 80 % predict ; note : one baseline value FEV1 use support inclusion criterion . Negative Human Immunodeficiency Virus ( HIV ) , HBSAg , Hepatitis C Virus ( HCV ) antibody screen test . Negative screening test : marijuana , cocaine metabolite , amphetamine , opiate , PCP , barbiturates , benzodiazepine , ethanol . Subjects follow laboratory criterion within provide range ( see Appendix B ) : Hemoglobin White blood cell ( WBC ) platelet count Alkaline phosphatase ( ALKP ) , total bilirubin , alanine aminotransferase ( ALT ) , Serum glucose ; note : nonfasting glucose perform abnormal , fast glucose measurement may obtain place ; within provide range , subject may enrol . Serum creatinine Activated partial thromboplastin time ( APTT ) fibrinogen Urine glucose blood test dipstick urinalysis negative . Urine protein test dipstick negative trace . Menstruating female fail inclusion due positive urine dipstick blood may retested follow cessation menses . Female subject must postmenopausal ( one year great without menses ) , surgically incapable childbearing , agreeable practice abstinence utilize two effective method birth control study period 12 week study product administration . Acceptable method may include : Intrauterine device Spermicide Barrier contraception Hormonal contraception A female subject must negative serum pregnancy test screen visit negative urine pregnancy test within 24 hour drug dosing . If male , agree use medically accept form contraception time enrollment 12 week study product administration . Agrees drink alcohol participate strenuous physical activity exercise 24 hour prior Day 1 Day 6 followup visit . Have receive investigational drug vaccine within 30 day prior study drug dose serious adverse reaction hypersensitivity drug . Is plan participate another clinical trial within 30 day last dose DAS181 . Have receive blood product within 6 month study enrollment . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Have liquid protein diet last month . Are allergic lactose . Have sickle cell disease . Have use prescription nonprescription drug , exclude hormonal contraception , within 7 day prior admission unless approve site PI subinvestigator . Subjects must willing refrain take nonstudy medication herbal supplement study Day 32 except approve site PI subinvestigator . Existence surgical , medical laboratory condition , judgment site PI subinvestigator , might interfere safety , distribution , metabolism , excretion drug . Subjects current previous history respiratory disease ( e.g. , asthma , allergic rhinitis , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , emphysema , anaphylaxis ) require acute chronic medication , determine investigator medical history evaluation physical examination . Subjects experience previous episode acute upper respiratory tract infection , pneumonia , otitis , bronchitis , sinusitis within 2 week prior screen . Subjects concurrent sustain respiratory symptom ( runny nose , sore throat , sneeze , cough , wheeze ) . Subjects oral temperature 37.8 degree C ( 100 degree F ) . Subjects cancer history hematologic malignancy . Cancer define active neoplastic disease , exclude noninvasive basal cell carcinoma . Subjects plan hospital admission cause and/or plan surgical procedure within 30 day initiation study . Female subject pregnant breastfeeding . Subjects donate lose 500mL blood three month prior screen plan donate blood study participation . Subjects clinically significant medical psychological condition would compromise subject 's safety , influence result study , affect subject 's ability participate study , impair subject 's ability provide inform consent . Subjects history drug dependence , psychiatric illness within 2 year study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 5, 2017</verification_date>
	<keyword>DAS181</keyword>
	<keyword>Influenza</keyword>
	<keyword>inhalation</keyword>
	<keyword>inpatient clinic</keyword>
	<keyword>Multi-Dose</keyword>
	<keyword>recombinant neuraminidase</keyword>
</DOC>